番紅花 Saffron × 焦慮

結論:證據支持但有警示

L1 Examine 在 Anxiety Disorders (Other) 主結果給 Grade B(3 RCTs, n=180, Small Improvement),L2 兩篇 2021/2023 MA(PMID 31987241 n=945 WMD -2.

B 🟡 B 初步證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 🇹🇼 台灣在地警示

L1 Examine 在 Anxiety Disorders (Other) 主結果給 Grade B(3 RCTs, n=180, Small Improvement),L2 兩篇 2021/2023 MA(PMID 31987241 n=945 WMD -2.19;PMID 31135916 n=1006 SMD -0.95)方向一致顯示焦慮分數顯著下降,且 4 篇 2020-2023 雙盲 RCT 都呈現 positive 或 mixed-positive。

然而:(1) 兩篇 MA 異質性 I²~80%,pooled 點估計可信度受限;(2) 多數 RCT 樣本小(n<100)、療程短(4-8 週),且收案族群混雜(亞臨床焦慮、合併憂鬱、青少年),對診斷性焦慮疾患外推有限;(3) RCTs 多集中於伊朗單一國家試驗中心,文化/遺傳代表性未驗證;(4) Affron 標準化萃取物的關鍵 RCT(PMID 29510352, 28735826)為產業資助。

整體證據方向一致、效應量中至大、但異質性與品質限制使其不應升至 Grade A,維持 Grade B(『初步證據、方向一致但證據強度受限』)與 Examine 一致。

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.68
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
77%
證據方向大致一致
證據層級
E2
多篇高品質統合分析(≥2 篇一致)

各層「支持此療效」的程度

分數越低=該層越不支持
L1 Examine國際基準
0.50
L5 臨床機構權威立場
0.60
L3 機轉生理合理性
0.65
L11 AI 複核獨立判讀
0.65
L2 PubMed原始文獻
0.85
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.683
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis
PMID: 31135916 2019 統合分析 n = 1,006
結論:Across reviewed RCTs, saffron showed consistent anxiolytic effect signal at 30-100 mg/day with HAM-A reduction; SR concluded mental health benefits plausible but RCTs small and short
🟠 品質有限
前往 PubMed
The effects of saffron (Crocus sativus L.) on mental health parameters and C-reactive protein: A meta-analysis of randomized clinical trials
PMID: 31987241 2021 統合分析 n = 945
結論:Saffron significantly improved anxiety scores compared with placebo (WMD -2.19, 95% CI -3.83 to -0.55; p=0.009); also reduced depression and improved BDNF; high heterogeneity
效應量:[object Object]
前往 PubMed
A double-blind, randomized and placebo-controlled trial of Saffron (Crocus sativus L.) in the treatment of anxiety and depression
PMID: 27101556 2016 RCT (double-blind) n = 60
結論:Saffron group showed significantly greater reductions in HAM-A and BAI scores vs placebo at week 6 (p<0.001); no serious adverse events
學術資助
前往 PubMed
Affron, a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: A randomised, double-blind, placebo-controlled study
PMID: 29510352 2018 RCT (double-blind) n = 80
結論:Saffron-treated youth (12-16y) showed significantly greater improvement in internalizing/anxiety subscale per youth self-report vs placebo over 8 weeks; parent-rated outcomes did not significantly differ
⚠️ 廠商資助
前往 PubMed
affron® a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial
PMID: 28735826 2017 RCT (double-blind) n = 56
結論:Saffron group showed significant reductions in DASS-21 anxiety (p<0.05) and depression subscales vs placebo at 4 weeks; effect size moderate
⚠️ 廠商資助
前往 PubMed
Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis
PMID: 31135916 2019 系統性回顧
結論:Across reviewed RCTs, saffron showed consistent anxiolytic effect signal at 30-100 mg/day with HAM-A reduction; SR concluded mental health benefits plausible but RCTs small and short
🟠 品質有限
前往 PubMed

L4a US FDA
謹慎
Saffron (Crocus sativus L.); CAS 977051-90-3; 21 CFR 73.500, 182.10; COLOR OR COLORING ADJUNCT, FLAVOR ENHANCER, FLAVORING AGENT OR ADJUVANT. 來源↗
L4b EU EFSA
反對
a cause and effect relationship has not been established 來源↗
L4c UK NHS
中性
— 本適應症無對應資料
L4d TW TFDA / 衛福部
謹慎
番紅花(Crocus sativus L.)之柱頭可供食品使用 來源↗
L4e WHO
中性
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
未表態
— 本適應症無對應資料
L5b Mayo Clinic
中性
— 本適應症無對應資料
L5c Cleveland Clinic
支持
Saffron may help ease symptoms of anxiety and depression 來源↗
L5d Harvard Health
中性
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
中性
— 本適應症無對應資料

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 極高
📍立場總覽

台灣社群關於番紅花的討論以「助眠/舒壓」為主軸,焦慮多屬附帶感受而非主要討論點;PTT regimen 板有少數正面實測(睡眠變深、白天較不緊張),WomenTalk 則多在料理、月經與假貨脈絡。整體屬助眠保健品連帶提及焦慮,真實鄉民焦慮實測樣本少、共識不足。

💬社群實感

分歧偏少(助眠回饋偏正面、焦慮抗緊張屬附帶主觀感受,專門針對焦慮的鄉民實測樣本稀少、無共識)

破解迷思 社群最常見的 4 個誤解
事實把助眠效果直接等同於抗焦慮療效(社群實測多落在睡眠面向,抗焦慮多為附帶主觀感受,非研究級證據)
事實誤以為番紅花保健食品可取代抗焦慮/抗憂鬱處方藥(社群與證據皆不支持,躁鬱症患者更應避免)
事實誤以為效果來自一般食用香料劑量(社群常把料理用番紅花與標準化萃取 Affron 28-30mg 混為一談,劑量差異大)
事實誤信『番紅花會大量出血/滑胎』的甄嬛傳式說法(需極大量才有風險,被網友指為誇大;但孕期仍建議避免)
🩹 社群通報的副作用
  • 口乾
  • 頭暈、嗜睡
  • 噁心、食慾改變
  • 頭痛
  • 高劑量或假貨疑慮(網友提醒『小心很多假貨』)
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • Affron(西班牙專利標準化番紅花萃取,社群與保健品文最常被點名的關鍵成分)
  • 日珂睡眠 Cupid(PTT regimen 板提及,番紅花併 B6/B12/葉酸/鎂/鈣助眠複方)

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

伊朗番紅花花絲 1g

代表來源 ↗
L10b · TFDA 法定身份 官方認定

本品為鳶尾科植物番紅花

來源 ↗

  • 認知行為治療(CBT)
  • 選擇性血清素回收抑制劑(SSRI)
  • 規律運動
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 6 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v30 engine_version: v1.0 claim_id: CLM-COND-anxiety-INT-saffron-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-anxiety-INT-saffron-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "番紅花能改善焦慮",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 3,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟡 B 初步證據"
  }
}